Drug Profile
Pacanalotamab - Amgen
Alternative Names: AMG-420; BI 836909Latest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Micromet Inc
- Developer Amgen; Boehringer Ingelheim
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 19 Jan 2024 Discontinued - Phase-I for Multiple myeloma (Recurrent, Second-line therapy or greater) in USA (IV)
- 05 Jan 2024 Discontinued - Phase-I for Multiple myeloma (Recurrent, Second-line therapy or greater) in Australia (IV)
- 05 Jan 2024 Discontinued - Phase-I for Multiple myeloma (Recurrent, Second-line therapy or greater) in Belgium (IV)